Esperion Therapeutics, Inc.2024财年第三财季实现净利润-29.52百万美元，同比增加28.44%

市场透视11-17

11月17日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2024财年第三财季净利润为-29.52百万美元，同比增加28.44%；其中营业收入为51.63百万美元，同比增加51.99%，每股基本收益为-0.15美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债6.84亿美元，其中短期债务41.14...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484510922?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2484510922","market":"us","top_or_hot":-1,"title":"Esperion Therapeutics, Inc.2024财年第三财季实现净利润-29.52百万美元，同比增加28.44%","media":"市场透视","content":"<div>\n<p>11月17日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2024财年第三财季净利润为-29.52百万美元，同比增加28.44%；其中营业收入为51.63百万美元，同比增加51.99%，每股基本收益为-0.15美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债6.84亿美元，其中短期债务41.14...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000026a23e04ac&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics, Inc.2024财年第三财季实现净利润-29.52百万美元，同比增加28.44%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics, Inc.2024财年第三财季实现净利润-29.52百万美元，同比增加28.44%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000026a23e04ac&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月17日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2024财年第三财季净利润为-29.52百万美元，同比增加28.44%；其中营业收入为51.63百万美元，同比增加51.99%，每股基本收益为-0.15美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债6.84亿美元，其中短期债务41.14...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000026a23e04ac&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000026a23e04ac&s=b","article_id":"2484510922","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000026a23e04ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2484510922","pubTimestamp":1731772811,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月17日，Esperion Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-29.52百万美元，同比增加28.44%；其中营业收入为51.63百万美元，同比增加51.99%，每股基本收益为-0.15美元。机构评级：截至2024年11月17日，当前有6家机构对Esperion Therapeutics, Inc.目标价做出预测，其中目标均价为7.51美元，其中最低目标价为2.05美元，最高目标价为16.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ESPR":"Esperion Therapeutics Inc."},"translate_title":"Esperion Therapeutics, Inc. achieved net profit of-US $29.52 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 28.44%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ESPR":0.9},"content_text":"11月17日，Esperion Therapeutics, Inc.（ESPR.US）公布财报，公告显示公司2024财年第三财季净利润为-29.52百万美元，同比增加28.44%；其中营业收入为51.63百万美元，同比增加51.99%，每股基本收益为-0.15美元。从资产负债表来看，Esperion Therapeutics, Inc.（ESPR.US）总负债6.84亿美元，其中短期债务41.14百万美元，资产负债比为0.46，流动比率为1.86。机构评级：截至2024年11月17日，当前有6家机构对Esperion Therapeutics, Inc.目标价做出预测，其中目标均价为7.51美元，其中最低目标价为2.05美元，最高目标价为16.00美元。公司简介：Esperion Therapeutics Inc 是一家制药公司。该公司专门从事为低密度脂蛋白胆固醇升高患者开发和商业化可获得，口服，每日一次的非他汀类药物。该公司的业务包括研究，开发和商业化治疗低密度脂蛋白胆固醇升高患者的疗法。其产品包括 NEXLETOL，NEXLIZET，NILEMDO 和 NUSTENDI。公司在一个运营分部管理其业务，即研究，开发和商业化治疗低密度脂蛋白胆固醇升高患者的疗法。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484510922"}